Zuoli Pharmaceutical announced that the company and its controlling subsidiary Qinghai Zhufeng Cordyceps Sinensis Pharmaceutical have a total of four products selected for the National Essential Medicines List, 2026 edition. The newly added product is Bailing Capsules, while Wuling Capsules, Lingze Tablets, and Bailing Tablets, which were already included in the 2018 edition, continue to be listed this time. In the first quarter of 2026, Zuoli Pharmaceutical achieved revenue of 898 million yuan and net profit attributable to the parent company of 200 million yuan.
Four products included in National Essential Medicines List, including new addition Bailing Capsules
